XERS News and Press, Xeris Pharmaceuticals Inc. From 09/10/19

The FDA approves Xeris Pharmaceuticals' ( XERS +0.9% ) GVOKE (glucagon), a ready-to-use, room temperature-stable liquid glucagon for the treatment of severe hypoglycemia (low blood sugar) in diabetics at least two years old. It will be available in prefilled syringe and autoinjector (Hyp...

Provides up to three years of interest only and extension of maturity date Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formul...

First approval for Xeris is based on positive efficacy and safety results from multiple clinical studies GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for pediatric and adult patients with diabetes ages 2 years and above or caregivers to rapid...

The following slide deck was published by Xeris Pharmaceuticals, Inc. in conjunction with this Read more ...

Xeris Pharmaceuticals Inc. ( XERS ) has a PDUFA on September 10, 2019, for a device-drug combo that delivers room-temperature, ready-to-use glucagon to hypoglycemia patients. Last year, around September, a month before its NDA was accepted by the FDA, the stock traded at its all-time high of a...

Xeris Pharmaceuticals' ( XERS ) share price took a huge hit following the FDA decision to extend Gvoke’s PDUFA date by 90 days due to a major amendment to the NDA. I jumped on the opportunity to add to my speculative position. Since then, the share price has recovered and is holding jus...

CHICAGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on August 28, 2019, ...

CHICAGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. ...

The following slide deck was published by Xeris Pharmaceuticals, Inc. in conjunction with this Read more ...

The following companies have filed prospectuses for mixed shelf offerings: More news on: Neuronetics, Inc., Xenon Pharmaceuticals Inc., Xeris Pharmaceuticals, Inc., Healthcare stocks news, Read more ...